Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
formalin-inactivated whole-cell non-typeable Haemophilus influenzae
- Development stage
- Unknown
- Lead developer
- Bioxyne
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Formalin-inactivated whole-cell non-typeable Haemophilus influenzae (NTHi) is an oral immunotherapeutic and vaccine developed by The University of Newcastle Research Associates (TUNRA) Ltd and Hunter Immunology (later acquired by Bioxyne and licensed to Mariposa Health). The active ingredient consists of lyophilized, formalin-killed whole-cell NTHi (specifically strain NTHi-164), formulated as an enteric-coated tablet (referred to as HI-164OV) to protect against gastric acid. Administered orally, the vaccine targets the mucosal immune system by stimulating gut-associated lymphoid tissue (Peyer's patches). This activates Th17 cells, NTHi-specific T cells, and immunoglobulins (IgG and IgA) that traffic to the respiratory tract, enhancing bacterial clearance and reducing airway inflammation. It is primarily developed for the prevention and treatment of recurrent acute bronchitis and acute exacerbations of chronic obstructive pulmonary disease (COPD) or chronic airway disease.
- Other names
- inactivated non-typeable Haemophilus influenzaeoral inactivated non-typeable Haemophilus influenzaelyophilized formalin-killed whole-cell NTHiNTHi-164NTHi164NTHi 164
02
Targets
γδ TCR (T-cell receptor)TLR4 (Toll-like receptor 4)TLR9 (Toll-like receptor 9)Complement (Complement system)TLR2 (Toll-like Receptor 2)B-cell receptor / antibody repertoire recognizing non-typeable Haemophilus influenzae surface antigens
Beyond the preview
Go deeper on formalin-inactivated whole-cell non-typeable Haemophilus influenzae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on formalin-inactivated whole-cell non-typeable Haemophilus influenzae.